BACKGROUND/AIM: It is important to delay the emergence of castration-resistant phenotype to improve the prognosis in patients with metastatic castration-sensitive prostate cancer (mCSPC). The objective of this study was to investigate the prognostic impact of time to castration resistance (TTCR) in mCSPC patients. PATIENTS AND METHODS: This study included 437 consecutive mCSPC patients whose primary androgen deprivation therapy was judged to have failed. Prognostic outcomes in these patients were investigated by dividing them into the following 4 groups of 82, 104, 133 and 118 patients with TTCR 0-6, 6.1-12, 12.1-18 and ≥18.1 months, respectively. RESULTS: The mean value of TTCR in the 437 patients was 18.7 months. Of several baseline parameters, significant differences among the 4 groups were noted in the performance status, prostate-specific antigen (PSA) level, lactate dehydrogenase (LDH) level, alkaline phosphatase (ALP) level and Gleason score, all of which favored longer TTCR groups. Furthermore, despite the lack of a significant difference in time from the development of castration-resistant disease to death among the 4 groups, there was a significant difference in overall survival (OS) from diagnosis among these groups, showing prolonged OS proportional to TTCR. Univariate analysis identified the age, PSA level, LDH level, ALP level, Gleason score, visceral metastasis and TTCR as significant predictors of OS, of which only age, ALP level and TTCR were shown to be independently associated with OS on multivariate analysis. CONCLUSION: mCSPC patients with a longer TTCR are likely to achieve a more favorable OS. Copyright
BACKGROUND/AIM: It is important to delay the emergence of castration-resistant phenotype to improve the prognosis in patients with metastatic castration-sensitive prostate cancer (mCSPC). The objective of this study was to investigate the prognostic impact of time to castration resistance (TTCR) in mCSPC patients. PATIENTS AND METHODS: This study included 437 consecutive mCSPC patients whose primary androgen deprivation therapy was judged to have failed. Prognostic outcomes in these patients were investigated by dividing them into the following 4 groups of 82, 104, 133 and 118 patients with TTCR 0-6, 6.1-12, 12.1-18 and ≥18.1 months, respectively. RESULTS: The mean value of TTCR in the 437 patients was 18.7 months. Of several baseline parameters, significant differences among the 4 groups were noted in the performance status, prostate-specific antigen (PSA) level, lactate dehydrogenase (LDH) level, alkaline phosphatase (ALP) level and Gleason score, all of which favored longer TTCR groups. Furthermore, despite the lack of a significant difference in time from the development of castration-resistant disease to death among the 4 groups, there was a significant difference in overall survival (OS) from diagnosis among these groups, showing prolonged OS proportional to TTCR. Univariate analysis identified the age, PSA level, LDH level, ALP level, Gleason score, visceral metastasis and TTCR as significant predictors of OS, of which only age, ALP level and TTCR were shown to be independently associated with OS on multivariate analysis. CONCLUSION: mCSPC patients with a longer TTCR are likely to achieve a more favorable OS. Copyright
Authors: Mike Wenzel; Felix Preisser; Benedikt Hoeh; Maria Schroeder; Christoph Würnschimmel; Thomas Steuber; Hans Heinzer; Severine Banek; Marit Ahrens; Andreas Becker; Pierre I Karakiewicz; Felix K H Chun; Luis A Kluth; Philipp Mandel Journal: Front Oncol Date: 2021-04-23 Impact factor: 6.244
Authors: Martin J Connor; Mesfin G Genie; David Burns; Edward J Bass; Michael Gonzalez; Naveed Sarwar; Alison Falconer; Stephen Mangar; Tim Dudderidge; Vincent Khoo; Mathias Winkler; Hashim U Ahmed; Verity Watson Journal: Eur Urol Open Sci Date: 2021-12-20
Authors: Martin John Connor; Mesfin G Genie; Michael Gonzalez; Naveed Sarwar; Kamalram Thippu Jayaprakash; Gail Horan; Feargus Hosking-Jervis; Natalia Klimowska-Nassar; Johanna Sukumar; Tzveta Pokrovska; Dolan Basak; Angus Robinson; Mark Beresford; Bhavan Rai; Stephen Mangar; Vincent Khoo; Tim Dudderidge; Alison Falconer; Mathias Winkler; Verity Watson; Hashim Uddin Ahmed Journal: BMJ Open Date: 2021-11-18 Impact factor: 2.692